Sameer Chaudhary*, Zeyaul Islam, Vijaya Mishra, Sakshi Rawat, Ghulam Md. Ashraf* and Prasanna R. Kolatkar* Pages 495 - 504 ( 10 )
The transcription factor Sox2 plays an important role in various phases of embryonic development, including cell fate and differentiation. These key regulatory functions are facilitated by binding to specific DNA sequences in combination with partner proteins to exert their effects. Recently, overexpression and gene amplification of Sox2 has been associated with tumor aggression and metastasis in various cancer types, including breast, prostate, lung, ovarian and colon cancer. All the different roles for Sox2 involve complicated regulatory networks consisting of protein-protein and protein-nucleic acid interactions. Their involvement in the EMT modulation is possibly enabled by Wnt/ β-catenin and other signaling pathways. There are number of in vivo models which show Sox2 association with increased cancer aggressiveness, resistance to chemo-radiation therapy and decreased survival rate suggesting Sox2 as a therapeutic target. This review will focus on the different roles for Sox2 in metastasis and tumorigenesis. We will also review the mechanism of action underlying the cooperative Sox2- DNA/partner factors binding where Sox2 can be potentially explored for a therapeutic opportunity to treat cancers.
HMG domain, endodermal-mesenchymal transition, transcription factor, tumor propagation, metastasis, overexpression, Wnt/β-catonin.
RASA Life science Informatics, Pune, Maharashtra, Diabetes Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), PO Box 34110, Doha, RASA Life science Informatics, Pune, Maharashtra, RASA Life science Informatics, Pune, Maharashtra, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Diabetes Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), PO Box 34110, Doha